ANXA5 and chronic kidney disease: Bissinger et al. conducted a cross-sectional study involving 122 NDD-CKD patients (spanning stages G1 to G5) and 133 healthy controls, demonstrating that NDD-CKD patients exhibited a ∼1.4-fold higher eryptosis rate (quantified via annexin V binding using flow cytometry) compared to controls.